Roche
Search results
Lonza Singapore is a mammalian cell culture and cell and gene therapy CDMO of biopharmaceutical products, including monoclonal antibodies (mAbs), cellular therapeutics and other recombinant proteins.
- Lonza to Expand Development Services for Mammalian Products in Singapore
The addition of new technology, alongside the increase in...
- bioscience.lonza.com
Discover Lonza Bioscience's innovative solutions for life...
- Lonza to Expand Development Services for Mammalian Products in Singapore
Oct 7, 2021 · The addition of new technology, alongside the increase in capacity and headcount of Lonza’s development services team in Singapore, will provide a comprehensive offering for small- and large-scale GMP mammalian manufacturing services and cell therapy capabilities.
Jan 10, 2024 · Lonza Biologics Tuas Pte Ltd. https://www.lonza.com/about-us/our-locations/tuas-singapore. Lonza is a preferred global partner to the pharmaceutical, biotech, and nutrition markets, focusing on enabling treatments that prevent illness and support healthier lifestyles.
Oct 11, 2021 · Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.
On 31-Aug, Genentech Singapore – which is wholly-owned by Roche, has announced that it will buy Lonza manufacturing facility in Singapore at a purchase price of US$290 million plus additional milestone payments of US$70 million.
Oct 21, 2011 · Singapore Exchange (“SGX”) is pleased that Lonza Group Ltd (“Lonza”), one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries, is listed today on its Mainboard by way of a secondary listing.
Discover Lonza Bioscience's innovative solutions for life science research and biomanufacturing in Singapore and beyond.
